Advances in Waldenström’s macroglobulinemia: significance of genetic alterations, current treatment strategies, & ongoing trials

This episode of the VJHemOnc Podcast spotlights advances in the understanding and treatment of Waldenström’s macroglobulinemia (WM), featuring Karan Chohan, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, Anna Maria Frustaci, MD, Niguarda Hospital, Milan, Italy, Neil Berinstein, MD, Sunnybrook Odette Cancer Centre, Toronto, Canada, Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, and Dima El-Sharkawi, MB, BS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK. The experts focus on the impact of MYD88 and TP53 alterations, current treatment approaches including the use of BTK inhibitors (BTKis), and strategies for patients who discontinue BTKis. They then go on to discuss clinical trial advances, including the BRAWM trial (NCT04624906) and BTK degraders.